Aspirin in Alzheimer's disease (AD2000): a randomised open-label trial
about
Aspirin, steroidal and non-steroidal anti-inflammatory drugs for the treatment of Alzheimer's diseaseNon-steroidal anti-inflammatory drugs as disease-modifying agents for Parkinson's disease: evidence from observational studiesNon-steroidal anti-inflammatory drugs as disease-modifying agents for Parkinson's disease: evidence from observational studiesTargeting innate immunity for neurodegenerative disorders of the central nervous systemAlzheimer's Disease: Exploring the Role of Inflammation and Implications for TreatmentContribution of blood platelets to vascular pathology in Alzheimer's diseaseNeuroinflammation in Alzheimer's disease; A source of heterogeneity and target for personalized therapyNeuroinflammation in Alzheimer's diseaseBrain microbleeds and Alzheimer's disease: innocent observation or key player?Aspirin for vascular dementia.Targeting cyclooxygenases-1 and -2 in neuroinflammation: Therapeutic implications.Role of amyloid peptides in vascular dysfunction and platelet dysregulation in Alzheimer's diseaseEffects of non-steroidal anti-inflammatory drug treatments on cognitive decline vary by phase of pre-clinical Alzheimer disease: findings from the randomized controlled Alzheimer's Disease Anti-inflammatory Prevention Trial.Alzheimer's Disease: Fatty Acids We Eat may be Linked to a Specific Protection via Low-dose Aspirin.Neuroinflammation impairs adaptive structural plasticity of dendritic spines in a preclinical model of Alzheimer's disease.Diagnosis and treatment of dementia: 4. Approach to management of mild to moderate dementia.The role of low-dose aspirin in the prevention of colorectal cancer.Concise review: Can stem cells be used to treat or model Alzheimer's disease?Recommended measures for the assessment of cognitive and physical performance in older patients with dementia: a systematic reviewType-I interferon pathway in neuroinflammation and neurodegeneration: focus on Alzheimer's disease.Low-Dose Aspirin Use and Cognitive Function in Older Age: A Systematic Review and Meta-analysis.Forget about thrombosis: Platelets and Alzheimer's disease, yet another sticky situation.Aspirin increases metabolism through germline signalling to extend the lifespan of Caenorhabditis elegans.Are inflammatory profiles the key to personalized Alzheimer's treatment?Treatment of vascular dementia. Recommendations of the Scientific Department of Cognitive Neurology and Aging of the Brazilian Academy of Neurology.Targeting Neuroinflammation to Treat Alzheimer's Disease.Stress-Induced Alterations of Immune Profile in Animals Suffering by Tau Protein-Driven Neurodegeneration.Aspirin increases NMDA receptor subunit 2A concentrations in rat hippocampus.Innate immune activation in Alzheimer’s disease.Anti-neuroinflammatory Potential of Natural Products in Attenuation of Alzheimer's Disease.Membrane-Modulating Drugs can Affect the Size of Amyloid-β Aggregates in Anionic Membranes
P2860
Q24203739-36C36288-3357-40F7-8D11-91BBFFBB6434Q24235107-B61140C8-DDC5-424C-A604-5FF6B7DDBF54Q24236199-BB0E0CAB-6A6E-4968-AEEF-10E035FD45A7Q26744219-DE24B822-FE64-4AB4-949E-614CAA141C35Q26776157-11025A69-615E-4144-B266-DF577EAA467EQ26861509-7EE94036-6CC8-4CA9-83CB-D541B1DBBBAFQ27014919-1F432EDF-BAB9-4ACB-A695-AC26141126EFQ28259238-4C9641F2-6FDD-433D-A467-A0C1D23A423BQ33800668-371D3C05-A791-4022-8D18-283D0C801D17Q33909196-A8CB565A-09CB-44D4-8267-DCE58FCDA317Q34432388-38FB12DB-ACA6-409A-A7EB-DAB3C8474889Q35141182-F22EE41F-B7F8-48FC-85A3-553CD06855CCQ35523832-8FF2F78F-AB73-4370-A647-B074C39524ECQ35806684-466C085D-85CF-4C99-A9D5-7EA55F759644Q36465116-C275D962-A82B-402B-83B3-143EDC33C084Q36909920-1ACA27BF-FC6B-47C2-B649-E5A10184F5EEQ37982139-ADCBDACC-969C-4715-A996-486B11C8BBCBQ38045262-59090847-6ECC-45F7-B3E1-487F7B985888Q38076109-5CA7B9E2-3530-40B8-A7DE-7E654FE1AF24Q38693735-8077FE13-BE09-49B2-A12A-C11192FD7292Q38829409-1F60CF60-4937-4645-8705-957B432C8290Q38843564-9081FB0F-895B-4129-9E1A-C9115F17F982Q41072898-2F463D2C-C713-4BA5-8692-25901C96FA5BQ41537684-F19DED22-E33D-46FF-BD0C-C92E2D607754Q47128027-0FB0B2A2-AC79-4C0D-9E49-C8C30361BBEEQ47188911-1036987E-9BB3-4C43-B15D-1AD4C8069CCEQ48281041-C8FB6082-D6D3-45B7-8E15-4ED09738149DQ48775929-6D3117A5-0FEE-46B1-98E0-CB0A00F22EB2Q55289589-983B7784-EA61-4862-91CE-9937A956BD27Q55363040-CF3B98C9-E0CE-42F2-A38C-AC8815883A44Q58771409-020E3E65-832E-4D49-879F-5DF4C006EFFF
P2860
Aspirin in Alzheimer's disease (AD2000): a randomised open-label trial
description
2008 nî lūn-bûn
@nan
2008 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Aspirin in Alzheimer's disease (AD2000): a randomised open-label trial
@ast
Aspirin in Alzheimer's disease (AD2000): a randomised open-label trial
@en
Aspirin in Alzheimer's disease (AD2000): a randomised open-label trial
@nl
type
label
Aspirin in Alzheimer's disease (AD2000): a randomised open-label trial
@ast
Aspirin in Alzheimer's disease (AD2000): a randomised open-label trial
@en
Aspirin in Alzheimer's disease (AD2000): a randomised open-label trial
@nl
prefLabel
Aspirin in Alzheimer's disease (AD2000): a randomised open-label trial
@ast
Aspirin in Alzheimer's disease (AD2000): a randomised open-label trial
@en
Aspirin in Alzheimer's disease (AD2000): a randomised open-label trial
@nl
P2093
P1433
P1476
Aspirin in Alzheimer's disease (AD2000): a randomised open-label trial
@en
P2093
AD2000 Collaborative Group
E Sellwood
P356
10.1016/S1474-4422(07)70293-4
P407
P577
2008-01-01T00:00:00Z